Premier Biomedical, Inc.

OTCPK:BIEI Stock Report

Market Cap: US$1.4m

Premier Biomedical Past Earnings Performance

Past criteria checks 0/6

There is insufficient data on Premier Biomedical's performance over the last few years.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth raten/a
Return on equityn/a
Net Marginn/a
Last Earnings Update31 Dec 2019

Recent past performance updates

No updates

Recent updates

In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Premier Biomedical has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.

Show section

Revenue & Expenses Breakdown
Beta

How Premier Biomedical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:BIEI Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 190000
30 Sep 190-110
30 Jun 190-110
31 Mar 190-110
31 Dec 180010
30 Sep 180-110
30 Jun 180310
31 Mar 180210
31 Dec 170-410
30 Sep 170-300
30 Jun 170-700
31 Mar 170-700
31 Dec 160-210
30 Sep 160-210
30 Jun 160-210
31 Mar 160-210
31 Dec 150-320
30 Sep 150-330
30 Jun 150-330
31 Mar 150-220
31 Dec 140-110
30 Sep 140-210
30 Jun 140-320
31 Mar 140-320
31 Dec 130-540
30 Sep 130-650

Quality Earnings: Insufficient data to determine if BIEI has high quality earnings.

Growing Profit Margin: Insufficient data to determine if BIEI's profit margins have improved over the past year.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if BIEI's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare BIEI's past year earnings growth to its 5-year average.

Earnings vs Industry: Insufficient data to determine if BIEI's earnings growth over the past year exceeded the Biotechs industry average.


Return on Equity

High ROE: BIEI has a negative Return on Equity (0%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.